KYG9TY5A1016 - Common Stock
ZURA BIO LTD
NASDAQ:ZURA (5/8/2024, 7:00:03 PM)
After market: 4.71 0 (0%)4.71
+0.07 (+1.51%)
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California. The company went IPO on 2021-07-16. The firm is advancing immunology assets into phase II development programs, including ZB-168 and torudokimab. ZB-168 is an anti-interleukin-7 receptor subunit alpha (IL7Rα) inhibitor that has the potential to impact diseases driven by interleukin-7 (IL7) and thymic stromal lymphopoietin (TSLP) biological pathways. The firm focuses on developing a portfolio of therapeutic indications for ZB-168 that build on existing Phase Ib data in type 1 diabetes demonstrating a safety profile and biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes interleukin-33 (IL33), and is in the phase II clinical development stage.
ZURA BIO LTD
4225 Executive Square, Suite 600
La Jolla CALIFORNIA
P: 18582470520
Employees: 0
Website: https://zurabio.com/
Biotech company Redx Pharma Plc is set to pull its shares from the London Stock Exchange’s smallest market, citing liquidity constraints and saying it will attract investors more easily as a private company.
ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zura Bio (NASDAQ:ZURA) just reported results for the fourth quarter of 2023.Zur...
Here you can normally see the latest stock twits on ZURA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: